<?xml version="1.0" encoding="UTF-8"?>
<document>
<type>mainstream</type>
<forum>http://feeds.feedburner.com/AmericanBankingNews</forum>
<forum_title>American Banking News</forum_title>
<discussion_title>Applied Genetic Technologies Corp (AGTC) Given “Buy” Rating at Roth Capital</discussion_title>
<language>english</language>
<gmt_offset></gmt_offset>
<topic_url>http://www.americanbankingnews.com/2016/04/25/applied-genetic-technologies-corp-agtc-given-buy-rating-at-roth-capital/</topic_url>
<topic_text>
Tweet 
Applied Genetic Technologies Corp (NASDAQ:AGTC) ‘s stock had its “buy” rating reaffirmed by Roth Capital in a research report issued on Monday, MarketBeat reports. 
Shares of Applied Genetic Technologies Corp ( NASDAQ:AGTC ) traded down 2.26% during mid-day trading on Monday, reaching $17.75. The company’s stock had a trading volume of 74,197 shares. Applied Genetic Technologies Corp has a 12-month low of $10.89 and a 12-month high of $22.02. The firm’s 50-day moving average price is $15.09 and its 200 day moving average price is $15.26. The firm’s market cap is $320.16 million. 
Applied Genetic Technologies Corp (NASDAQ:AGTC) last released its quarterly earnings data on Monday, February 8th. The company reported $0.17 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.36. During the same quarter in the prior year, the company earned ($0.28) EPS. The company earned $12.20 million during the quarter, compared to analyst estimates of $8.76 million. The business’s revenue was up 1771.2% on a year-over-year basis. On average, analysts expect that Applied Genetic Technologies Corp will post ($0.10) EPS for the current year. 
AGTC has been the subject of several other research reports. Chardan Capital restated a “buy” rating and issued a $25.00 price objective on shares of Applied Genetic Technologies Corp in a research note on Sunday, January 10th. Zacks Investment Research upgraded shares of Applied Genetic Technologies Corp from a “sell” rating to a “hold” rating in a research note on Tuesday, January 26th. Stifel Nicolaus decreased their price objective on shares of Applied Genetic Technologies Corp from $32.00 to $29.00 and set a “buy” rating for the company in a research note on Tuesday, February 9th. Janney Montgomery Scott started coverage on shares of Applied Genetic Technologies Corp in a research note on Friday, March 18th. They issued a “buy” rating and a $23.00 price objective for the company. Finally, Cantor Fitzgerald restated a “buy” rating and issued a $32.00 price objective on shares of Applied Genetic Technologies Corp in a research note on Tuesday, February 9th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company. Applied Genetic Technologies Corp presently has an average rating of “Buy” and an average target price of $26.11. 
A number of hedge funds have recently added to or reduced their stakes in AGTC. Ridgeback Capital Investments L.P. purchased a new stake in Applied Genetic Technologies Corp during the fourth quarter valued at approximately $5,019,000. TFS Capital LLC boosted its stake in Applied Genetic Technologies Corp by 394.4% in the fourth quarter. TFS Capital LLC now owns 292,636 shares of the company’s stock valued at $5,970,000 after buying an additional 233,442 shares during the last quarter. Acadian Asset Management LLC boosted its stake in Applied Genetic Technologies Corp by 234.3% in the first quarter. Acadian Asset Management LLC now owns 296,464 shares of the company’s stock valued at $4,145,000 after buying an additional 207,776 shares during the last quarter. Numeric Investors LLC boosted its stake in Applied Genetic Technologies Corp by 984.6% in the fourth quarter. Numeric Investors LLC now owns 226,689 shares of the company’s stock valued at $4,624,000 after buying an additional 205,789 shares during the last quarter. Finally, Emerald Mutual Fund Advisers Trust purchased a new stake in Applied Genetic Technologies Corp during the fourth quarter valued at approximately $4,190,000. 
Applied Genetic Technologies Corp is a United States-based clinical stage biotechnology company. The Company develops gene therapy products for the treatment of inherited and acquired diseases. Its products are used to treat Alpha One Antitrypsin Deficiency ( NASDAQ:AGTC ), a respiratory disease caused by deficiencies in the tissue protective protein alpha one antitrypsin; and Lebers congenital amaurosis, an inherited condition causing early blindness.  //www.americanbankingnews.com/2016/04/25/applied-genetic-technologies-corp-agtc-given-buy-rating-at-roth-capital/   Applied Genetic Technologies Corp   Applied Genetic Technologies Corp  
</topic_text>
<spam_score>0.00</spam_score>
<post_num>1</post_num>
<post_id>post-1</post_id>
<post_url>http://www.americanbankingnews.com/2016/04/25/applied-genetic-technologies-corp-agtc-given-buy-rating-at-roth-capital/</post_url>
<post_date>20160425</post_date>
<post_time>1840</post_time>
<username>ABMN Staff</username>
<post>
Tweet 
Applied Genetic Technologies Corp (NASDAQ:AGTC) ‘s stock had its “buy” rating reaffirmed by Roth Capital in a research report issued on Monday, MarketBeat reports. 
Shares of Applied Genetic Technologies Corp ( NASDAQ:AGTC ) traded down 2.26% during mid-day trading on Monday, reaching $17.75. The company’s stock had a trading volume of 74,197 shares. Applied Genetic Technologies Corp has a 12-month low of $10.89 and a 12-month high of $22.02. The firm’s 50-day moving average price is $15.09 and its 200 day moving average price is $15.26. The firm’s market cap is $320.16 million. 
Applied Genetic Technologies Corp (NASDAQ:AGTC) last released its quarterly earnings data on Monday, February 8th. The company reported $0.17 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.36. During the same quarter in the prior year, the company earned ($0.28) EPS. The company earned $12.20 million during the quarter, compared to analyst estimates of $8.76 million. The business’s revenue was up 1771.2% on a year-over-year basis. On average, analysts expect that Applied Genetic Technologies Corp will post ($0.10) EPS for the current year. 
AGTC has been the subject of several other research reports. Chardan Capital restated a “buy” rating and issued a $25.00 price objective on shares of Applied Genetic Technologies Corp in a research note on Sunday, January 10th. Zacks Investment Research upgraded shares of Applied Genetic Technologies Corp from a “sell” rating to a “hold” rating in a research note on Tuesday, January 26th. Stifel Nicolaus decreased their price objective on shares of Applied Genetic Technologies Corp from $32.00 to $29.00 and set a “buy” rating for the company in a research note on Tuesday, February 9th. Janney Montgomery Scott started coverage on shares of Applied Genetic Technologies Corp in a research note on Friday, March 18th. They issued a “buy” rating and a $23.00 price objective for the company. Finally, Cantor Fitzgerald restated a “buy” rating and issued a $32.00 price objective on shares of Applied Genetic Technologies Corp in a research note on Tuesday, February 9th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company. Applied Genetic Technologies Corp presently has an average rating of “Buy” and an average target price of $26.11. 
A number of hedge funds have recently added to or reduced their stakes in AGTC. Ridgeback Capital Investments L.P. purchased a new stake in Applied Genetic Technologies Corp during the fourth quarter valued at approximately $5,019,000. TFS Capital LLC boosted its stake in Applied Genetic Technologies Corp by 394.4% in the fourth quarter. TFS Capital LLC now owns 292,636 shares of the company’s stock valued at $5,970,000 after buying an additional 233,442 shares during the last quarter. Acadian Asset Management LLC boosted its stake in Applied Genetic Technologies Corp by 234.3% in the first quarter. Acadian Asset Management LLC now owns 296,464 shares of the company’s stock valued at $4,145,000 after buying an additional 207,776 shares during the last quarter. Numeric Investors LLC boosted its stake in Applied Genetic Technologies Corp by 984.6% in the fourth quarter. Numeric Investors LLC now owns 226,689 shares of the company’s stock valued at $4,624,000 after buying an additional 205,789 shares during the last quarter. Finally, Emerald Mutual Fund Advisers Trust purchased a new stake in Applied Genetic Technologies Corp during the fourth quarter valued at approximately $4,190,000. 
Applied Genetic Technologies Corp is a United States-based clinical stage biotechnology company. The Company develops gene therapy products for the treatment of inherited and acquired diseases. Its products are used to treat Alpha One Antitrypsin Deficiency ( NASDAQ:AGTC ), a respiratory disease caused by deficiencies in the tissue protective protein alpha one antitrypsin; and Lebers congenital amaurosis, an inherited condition causing early blindness.  //www.americanbankingnews.com/2016/04/25/applied-genetic-technologies-corp-agtc-given-buy-rating-at-roth-capital/   Applied Genetic Technologies Corp   Applied Genetic Technologies Corp  
</post>
<signature>

</signature>
<external_links>

</external_links>
<country>US</country>
<main_image>http://www.americanbankingnews.com/logos/applied-genetic-technologies-corp-logo.jpg</main_image>
</document>
